LLY vs NVS
ELI Lilly & Co. and Novartis AG, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | LLY | NVS |
|---|---|---|
| Revenue | $65.2B | $54.5B |
| Net income | $20.6B | $14.0B |
| Gross margin | 83.0% | 78.8% |
| Net margin | 31.7% | 25.6% |
| Return on equity | 101.2% | 31.0% |
| Diluted EPS | $22.95 | $7.15 |
| Dividend / share | $6.23 | — |
| Payout ratio | 26.1% | — |
| Free cash flow | — | $17.6B |
| Equity | $26.5B | $46.1B |
| Net debt / equity | 1.33× | 0.37× |
| Current ratio | 1.58× | 1.12× |
| Revenue CAGR 5y | 21.6% | 2.3% |
| Profit CAGR 5y | 27.2% | 11.6% |
LLY bills 1.2× the revenue of NVS, and keeps more of each dollar of revenue as profit (31.7% against 25.6%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | LLY | NVS |
|---|---|---|
| FY2025 | $65.2B | $54.5B |
| FY2024 | $45.0B | $50.3B |
| FY2023 | $34.1B | $45.4B |
| FY2022 | $28.5B | $42.2B |
| FY2021 | $28.3B | $42.8B |
| FY2020 | $24.5B | $48.7B |
| FY2019 | $22.3B | $47.5B |
| FY2018 | $21.5B | $44.8B |
| FY2017 | $20.0B | $42.4B |
| FY2016 | $21.2B | $48.5B |
Net income by year
Bottom line
| Fiscal year | LLY | NVS |
|---|---|---|
| FY2025 | $20.6B | $14.0B |
| FY2024 | $10.6B | $11.9B |
| FY2023 | $5.2B | $14.8B |
| FY2022 | $6.2B | $7.0B |
| FY2021 | $5.6B | $24.0B |
| FY2020 | $6.2B | $8.1B |
| FY2019 | $8.3B | $11.7B |
| FY2018 | $3.2B | $12.6B |
| FY2017 | $-204.1M | $7.7B |
| FY2016 | $2.7B | $6.7B |
Advertisement
AdSense · Rectangle 336×280